sever
viral
pneumonia
associ
high
mortal
rate
howev
due
vulner
critic
ill
patient
invas
diagnost
method
perform
caution
intens
care
unit
icu
would
help
preval
risk
factor
clinic
impact
viru
detect
elucid
evalu
patient
sever
pneumonia
januari
st
decemb
st
revers
transcriptionpolymeras
chain
reaction
rtpcr
analysi
perform
respiratori
virus
viral
pathogen
could
exclud
origin
sever
pneumonia
baselin
characterist
laboratori
result
microbiolog
find
clinic
outcom
patient
analyz
respiratori
virus
common
pathogen
adult
hospit
pneumonia
frequent
detect
bacteri
pathogen
certain
group
patient
influenza
viru
wellknown
respiratori
viral
pathogen
other
includ
respiratori
syncyti
viru
rsv
parainfluenza
viru
also
common
viral
pathogen
easili
distinguish
base
clinic
find
alon
therefor
suggest
revers
transcriptionpolymeras
chain
reaction
rtpcr
assay
perform
patient
viral
pathogen
suspect
test
respiratori
virus
decreas
inappropri
use
antibiot
medic
resourc
viral
pneumonia
also
major
caus
patient
deterior
intens
care
unit
icu
respiratori
virus
wellknown
high
preval
patient
commun
acquir
pneumonia
cap
exhibit
milder
clinic
present
furthermor
role
nosocomi
pathogen
sever
ill
group
patient
highlight
howev
limit
data
exist
regard
preval
respiratori
virus
among
healthcar
associ
pneumonia
hcap
hospitalacquir
pneumonia
hap
patient
addit
consid
narrow
rang
antivir
agent
respiratori
virus
potenti
harm
invas
respiratori
sampl
rtpcr
critic
ill
patient
crucial
reveal
patient
sampl
perform
whether
detect
lead
chang
clinic
manag
outcom
patient
studi
aim
identifi
presenc
common
respiratori
viral
pathogen
patient
sever
pneumonia
admit
icu
includ
cap
hcap
hap
addit
aim
analyz
risk
factor
clinic
impact
detect
conduct
retrospect
cohort
studi
adult
patient
admit
medic
icu
sever
pneumonia
januari
decemb
pneumonia
diagnos
attend
physician
combin
new
lung
infiltr
clinic
evid
includ
new
onset
fever
purul
sputum
leukocytosi
declin
oxygen
pneumonia
categor
cap
hcap
hap
accord
american
thorac
societi
infecti
diseas
societi
america
guidelin
respiratori
specimen
sampl
rtpcr
perform
attend
physician
consid
necessari
routin
care
studi
conduct
accord
amend
declar
helsinki
review
institut
review
board
seoul
nation
univers
hospit
protocol
number
institut
review
board
approv
studi
requir
inform
consent
waiv
data
deidentifi
analysi
rtpcr
analysi
perform
sever
pneumonia
respond
empir
antibacteri
agent
radiograph
find
reveal
ground
glass
opac
suggest
atyp
pathogen
patient
immun
compromis
decis
regard
type
specimen
collect
rtpcr
analysi
made
attend
physician
specimen
collect
includ
invas
bronchoalveolar
lavag
bal
noninvas
nasopharyng
swab
sputum
endotrach
aspir
method
howev
due
south
korea
nation
insur
polici
result
pathogen
influenza
viru
type
b
parainfluenza
viru
type
rsv
type
b
adenoviru
report
attend
physician
throughout
studi
period
baselin
characterist
patient
age
sex
acut
physiolog
chronic
health
evalu
ii
apach
ii
score
charlson
comorbid
index
cci
score
underli
comorbid
review
patient
chronic
obstruct
pulmonari
diseas
asthma
bronchiectasi
pneumoconiosi
tuberculosi
destroy
lung
defin
chronic
lung
diseas
laboratori
result
analyz
includ
white
blood
cell
count
platelet
count
creactiv
protein
level
clinic
outcom
includ
hospit
length
stay
day
icu
length
stay
day
chang
manag
inhospit
mortal
caus
inhospit
mortal
also
obtain
medic
record
death
certif
patient
patient
without
viru
detect
compar
term
baselin
demograph
laboratori
result
clinic
outcom
viral
detect
rate
describ
month
pneumonia
categori
pathogen
viral
bacteri
coinfect
specifi
bacteri
coinfect
consid
exist
virus
bacteria
detect
bacteria
consid
pathogen
blood
cultur
respiratori
tract
specimen
cultur
urin
pneumococc
antigen
reveal
posit
result
inform
impact
clinic
decis
obtain
retrospect
review
electron
medic
record
order
commun
system
categor
variabl
report
number
percentag
continu
variabl
report
median
interquartil
rang
iqr
mean
standard
deviat
sd
depend
pattern
distribut
statist
analys
perform
use
ibm
spss
softwar
version
ibm
corp
armonk
ny
graph
creat
use
prism
softwar
graphpad
softwar
san
diego
ca
twotail
pvalu
less
consid
statist
signific
patient
without
respiratori
viru
detect
show
signific
differ
term
age
sex
diseas
sever
present
apach
ii
score
howev
patient
commun
onset
histori
recent
week
chemotherapi
lower
platelet
count
higher
rate
viru
detect
addit
rate
rtpcr
detect
respiratori
viral
pathogen
show
season
rate
higher
februari
januari
lower
septemb
may
season
promin
cap
compar
hcap
hap
fig
clinic
outcom
length
hospit
stay
length
icu
stay
inhospit
mortal
differ
two
group
tabl
detect
rate
highest
invas
noninvas
sampl
perform
among
patient
among
patient
underw
type
sampl
new
inform
acquir
addit
invas
sampl
patient
addit
inform
obtain
patient
patient
result
invas
noninvas
sampl
patient
neg
result
addit
invas
sampl
among
patient
posit
rtpcr
result
rsv
common
pathogen
detect
n
follow
influenza
n
parainfluenza
n
rsv
b
n
adenoviru
n
influenza
b
n
parainfluenza
n
detect
rate
show
similar
distribut
divid
pneumonia
categori
except
influenza
tend
preval
commun
set
tabl
bacteri
coinfect
detect
patient
common
bacteri
pathogen
staphylococcu
aureu
n
follow
enterococcu
faecium
n
klebsiella
pneumonia
n
acinetobact
baumannii
n
pseudomona
aeruginosa
n
bacteria
commonli
detect
influenza
confirm
n
follow
rsv
n
parainfluenza
n
adenoviru
n
rsv
b
n
influenza
b
n
tabl
patient
bacteri
coinfect
higher
neutrophil
count
lower
lymphocyt
count
lower
ratio
bal
fluid
without
coinfect
otherwis
two
group
show
signific
differ
demograph
clinic
outcom
tabl
detect
viral
pathogen
led
chang
manag
diseas
patient
twelv
patient
receiv
antivir
therapi
oseltamivir
ribavirin
empir
antivir
therapi
continu
extend
patient
use
immunosuppress
agent
includ
steroid
decreas
stop
patient
staphylococcu
epidermidi
stenotrophomona
patient
antibiot
n
antivir
agent
n
discontinu
bacteri
pathogen
longer
suspect
detect
viru
effect
antivir
agent
tabl
clinic
outcom
length
hospit
stay
length
icu
stay
inhospit
mortal
compar
accord
chang
manag
howev
differ
statist
signific
tabl
studi
identifi
risk
factor
preval
clinic
impact
viru
detect
among
patient
sever
pneumonia
admit
medic
icu
respiratori
viral
infect
suspect
patient
commun
winter
season
patient
recent
chemotherapi
patient
low
serum
platelet
count
overal
viru
detect
rate
rsv
common
pathogen
influenza
viru
common
pathogen
bacteri
coinfect
detect
respiratori
virus
led
chang
manag
onethird
patient
viru
detect
rate
higher
februari
januari
well
patient
commun
onset
find
support
recommend
use
empir
therapi
influenza
viru
winter
season
hospit
cap
patient
patient
recent
chemotherapi
higher
risk
viral
pneumonia
consist
previou
knowledg
immunosuppress
risk
factor
influenza
viral
pneumonia
viru
detect
rate
highest
patient
undergon
invas
noninvas
sampl
n
inform
obtain
invas
sampl
approxim
patient
n
although
potenti
harm
bal
critic
ill
patient
must
thoroughli
review
procedur
invas
sampl
consid
select
patient
state
winter
season
commun
onset
recent
chemotherapi
low
platelet
count
addit
viru
detect
rsv
import
pathogen
result
sever
pneumonia
especi
elderli
common
pathogen
detect
previou
studi
differ
detail
distribut
pathogen
mani
report
common
viral
pathogen
includ
influenza
parainfluenza
rsv
consid
limit
strategi
treat
prevent
respiratori
virus
influenza
distribut
variou
pathogen
may
emphas
need
develop
novel
antivir
agent
vaccin
studi
first
specifi
clinic
impact
adultonset
sever
viral
pneumonia
accord
detect
respiratori
virus
previou
studi
conduct
children
milder
form
pneumonia
howev
children
much
higher
rate
respiratori
viral
ill
adult
discuss
separ
sever
pneumonia
interest
icu
set
among
patient
whose
manag
chang
common
chang
antivir
agent
n
current
antiinfluenza
agent
activ
use
antivir
agent
ribavirin
antivir
treatment
option
noninfluenza
respiratori
virus
studi
result
emphas
need
develop
novel
antivir
agent
respiratori
virus
apart
antivir
agent
respiratori
viral
detect
critic
ill
patient
led
reduct
cessat
immunosuppress
treatment
patient
use
highdos
steroid
known
associ
higher
mortal
rate
longer
viral
shed
influenza
patient
therefor
help
reduc
use
immunemodul
agent
includ
steroid
improv
patient
outcom
two
patient
stop
use
empir
antibiot
treatment
focus
respiratori
virus
pathogen
longterm
use
antibacteri
agent
patient
viral
pneumonia
known
increas
risk
develop
multidrugresist
pathogen
clostridium
difficil
infect
rather
improv
clinic
outcom
bacteri
coinfect
rate
present
studi
similar
previou
report
support
fact
patient
viral
infect
care
examin
addit
bacteri
infect
common
bacteri
pathogen
coinfect
common
colon
nasopharynx
howev
fail
show
signific
differ
mortal
relat
coinfect
result
also
consist
previou
report
show
compar
result
patient
without
bacteri
coinfect
consequ
bacteri
coinfect
requir
studi
studi
sever
limit
first
retrospect
studi
perform
singl
center
second
consid
detect
microorgan
pathogen
howev
detect
respiratori
viru
unlik
neutral
pathogen
certain
group
patient
accord
previou
report
although
studi
requir
possibl
invas
detect
respiratori
viru
taken
account
third
although
rtpcr
kit
institut
known
good
sensit
specif
risk
falseneg
perfectli
rule
fourth
detect
rate
lower
previou
report
limit
number
report
pathogen
inclus
hap
may
respons
result
patient
underw
multiplex
rtpcr
detect
respiratori
viral
pathogen
hap
patient
detect
rate
increas
cap
patient
consid
compar
result
recent
systemat
review
conclus
noninfluenza
respiratori
virus
commonli
detect
sever
pneumonia
patient
detect
viral
pathogen
patient
sever
pneumonia
lead
chang
clinic
manag
strategi
therefor
rtpcr
analysi
activ
perform
sever
pneumonia
icu
especi
among
risk
factor
viral
infect
furthermor
futur
effort
requir
develop
novel
antivir
agent
noninfluenza
respiratori
virus
support
inform
